Daniel Von Hoff
Chairman, Scientific Advisory Board
Daniel Von Hoff, MD, FACP, is a highly regarded medical oncologist and drug developer, serving in the role of Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, Chief Scientific Officer of the HonorHealth Research Institute, and Medical Director of Research as well as Chief Scientific Officer at US Oncology. Dr. Von Hoff and his team are focused on the development of new anticancer agents and the development of new treatments for patients. Dr. Von Hoff has been the founder and/or editor of numerous scientific publications including Molecular Cancer Therapeutics and Clinical Cancer Research. He was also a founder of ILEX TM Oncology, a company that had two anti-cancer agents approved by the FDA, Campath and Clolar. In addition, he has been on both the American Association for Cancer Research (AACR) and American Society of Clinical Oncology Board of Directors, is a past president of the AACR, is a fellow of the American College of Physicians and was a member of President Bush’s National Cancer Advisory Board from 2004 to 2010.